Royalty Pharma plc (RPRX)


Stock Price Forecast

April 26, 2024


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Royalty Pharma plc chart...

About the Company

We do not have any company description for Royalty Pharma plc at the moment.

Sector

Life Sciences

Industry

Pharmaceutical Preparations

Employees

92

Exchange

Nasdaq

$2B

Total Revenue

92

Employees

$0M

Market Capitalization

12.83

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $RPRX News

Royalty Pharma (NASDAQ:RPRX) Will Pay A Dividend Of $0.21

6d ago, source:

The board of Royalty Pharma plc ( NASDAQ:RPRX ) has announced that it will pay a dividend of $0.21 per share on ...

Royalty Pharma plc (RPRX) Shares Plummet Below 1-Year High

7mon ago, source: newsheater

Royalty Pharma plc (NASDAQ: RPRX)’s stock price has decreased by -1.21 compared to its previous closing price of 28.16. However, the company has seen a -1.52% decrease in its stock price over the last ...

Royalty Pharma Declares Second Quarter 2024 Dividend

9d ago, source:

The board of directors of (Nasdaq: RPRX) has approved the payment of a dividend for the second quarter of 2024 of $0.21 per Class A ordinary share. The dividend will be paid on June 14, 2024, to ...

Royalty Pharma declares $0.21 dividend

9d ago, source:

Payable June 14; for shareholders of record May 17; ex-div May 16.

SMALL CAP IDEA: Why investors should add Hemogenyx Pharmaceuticals to their watchlist

on MSN ago, source:

Investors can now add Hemogenyx Pharmaceuticals PLC to the watch list after it pulled off the near impossible by raising $4.2 ...

Top pharmaceutical company evaluates Optimer for precision liver medicine

4d ago, source: News Medical on MSN

The Optimer delivery vehicle was developed to selectively target cells linked to fibrotic liver disease, as part of a fee-for ...

i3 Energy PLC Announces Partial Sale of the Company's Royalty Assets

9d ago, source:

Retained Key Royalty Position at Greater Simonette: As part of i3's high-impact Montney oil asset at Simonette, the Company has retained its 16,160 acre royalty position, along with approximately 35 ...

Roche, Adaptimmune part ways on cell therapy research

14d ago, source: BioPharma Dive

The two companies have ended a collaboration that was struck in 2021 and focused on “off-the-shelf” cell therapies for cancer.

Wall Street plunges after US inflation shock

on MSN ago, source:

US stock markets plunged amid fears of stagflation in the American economy, which grew at its slowest pace in nearly two ...

Spirit of St. Louis: UFL's Battlehawks Are Proof of League's Concept

14d ago, source: Sportico on MSN

If Americans have largely greeted the latest wrinkle in spring football with a collective shrug and a polite, closed-mouth ...

Iterum Therapeutics plc (NASDAQ:ITRM) Q4 2023 Earnings Call Transcript

24d ago, source:

Q4 2023 Earnings Call Transcript March 28, 2024 Iterum Therapeutics plc beats earnings expectations. Reported EPS is $-0.94, ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...